Introduction: With the ageing population, diseases such as age-related macular degeneration 2 (AMD) will become more prevalent. This will increase demand for provision of care on 3 affected individuals, society and the healthcare system. To develop the best, individually 4 tailored treatment for every patient, however, remains challenging.
. Three GA phenotypes have been reported using cluster analysis with different 23 progression rates [25] , but our current understanding of the disease does not lend itself to 24 appropriate individual treatment to be initiated. The exact pathogenesis of AMD is still elusive due to its multifactorial etiology, which 29 includes a complex interplay between genetic and environmental factors. More than 50 single 30 nucleotide polymorphisms in 34 loci have been linked to AMD [26] , the most relevant being 31 CFH (in the complement pathway) and ARMS2 (unknown function). Other molecular 32 function. 23 The Age-Related Eye Disease Study (AREDS) found that oral supplementation of 24 antioxidants and zinc in patients with intermediate AMD (defined as patients with extensive 25 intermediate drusen, ≥1 large druse, extrafoveal GA, or late AMD or vision loss due to AMD 26 in at least one eye) reduced the risk of progression to nAMD by 25%. Unfortunately, 27 supplementation had no effect on the progression to GA [38] . Due to the association of beta-28 carotene with increased risk of lung cancer in smokers, the follow-up study, AREDS2, 29 substituted it in the original formulation by lutein and zeaxanthin, and also included omega-3 30 docosahexaenoic acid and eicosapentaenoic acid. [39] . None of the newly added constituents 31 increased the efficacy of the formulation, but inclusion of lutein and zeaxanthin instead of 1 beta-carotene is now recommended for safety reasons. Supplementation in the USA is 2 popular but in Europe it did not gain the same momentum [40] . 3 The mainstay of nAMD treatment is anti-angiogenic therapy delivered by intravitreal 4 injection targeting vascular endothelial growth factor (VEGF), a protein that stimulates 5 proliferation and permeability of new blood vessels [41] . In the Western World there are 6 currently 3 anti-VEGF treatments used: Ranibizumab (Lucentis ® , Novartis) [42] and 7 aflibercept (Eylea ® , Regeneron/Bayer) [43] were approved by the Food and Drug 8 Administration in 2006 and 2011 respectively, and bevacizumab (Avastin ® , Roche) is used 9 off-label since 2005. While previous treatment strategies such as laser photocoagulation [44] 10 and photodynamic therapy [45] with verteporfin resulted in slower vision loss than those 11 without treatment [45] , anti-angiogenic therapy improved visual acuity for the first time [42, 12 46 ]. However, the need for multiple injections, significant numbers of non-responders, 13 incident macular atrophy and high costs limit the potential benefits of anti-VEGF therapy in 14 the real-world setting [47] , and has slowed its introduction in the developing world. 15 There is currently no treatment to prevent, slow or recover the visual loss caused by GA. 16 Approaches targeting different disease pathways such as oxidative stress [39] , 17 neuroprotection [48], visual cycle modulation [49] , immunosuppression [50] or inflammation 18 [51] have all failed in clinical trials in recent years. One potential explanation for the lack of 19 success might be that the target population was inappropriately phenotyped and/or genotyped 20 [52]. Another is that trials were designed based on inadequate or outdated molecular 21 information [8, 53] or histopathology [54, 55, 56] . The need for more precise ultrastructural 22 and molecular understanding of GA had recently been address raised [12, 13, 57, 58] . 23 Excellent pathological descriptions do exist [59, 60] paving the way for further detailed 24 investigations. It is also possible that GA represents a spectrum of diseases resulting in 25 clinically similar RPE atrophy. For example, GA could develop by primary RPE damage or 26 as a secondary insult caused by primary, adjacent photoreceptor loss. In fact, the latter (called 27 "outer retinal atrophy") [61] occurs in the presence of reticular pseudodrusen, a special type 28 of extracellular deposit located interior to the RPE. The existence of different mechanisms 29 could explain the lack of efficacy of treatment on the overall GA population. 30 Given that there is only limited success in treating AMD patients, it signals that we still need 31 to improve our understanding of interactions between phenotype, genotype, biomarker and 32 environmental factors so we begin to understand individual affection rather than that of 1 population. 2 3 2. Precision medicine 4 5 Precision medicine can be defined as tailoring medical treatment to the individual 6 characteristics of each patient [62] . It is an emerging approach aimed at using genetic and 7 other biomarkers (e.g. proteins, ribonucleic acids, metabolites) in addition to clinical 8 examination to make a precise assessment of the individuals regarding the susceptibility to a 9 disease, the diagnostic and prognosis of a disease, and enable treatment decisions based on 10 the knowledge about biological processes of the disease pathogenesis for the individual.
Definitions and relevant regulations
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The diagnosis and staging of AMD is based, as described in section 1, on anatomical 12 characteristics of the retina (phenotypes) assessed by imaging modalities such as fundus 13 photography and more recently by SD-OCT. Similarly, the assessment of AMD prognosis, 14 especially for the risk of conversion from early/intermediate AMD to late AMD (neovascular 15 AMD or geographic atrophy) is mainly based on demographics and the fundus phenotype 16 [12] in the absence of suitable genetic marker. However, recent research shows that soon program. IAMDGC focuses on the analysis of AMD's genetic architecture, bridging the gap 25 between association studies of common variants and sequencing studies of rare variants. 26 However, phenotyping for IAMDGC is currently based on colour fundus images and, as 27 explained in 1.3., phenotyping of AMD is being reclassified based on new imaging 28 modalities and pathology. EYE-RISK consortium focuses on a broader range of both clinical 29 and basic science topics, including but not limited tonew biomarker identification for 30 patient stratification, development of new algorithms measuring the personalized risk for 31 progression to advanced AMD, elucidating AMD pathology pathways and finally, the 32 potential combination of these. One of the goals of Eye-Risk is to devise more advance 1 criteria for phenotype based on advancements in imaging as well as emerging molecular 2 information like metabolomics [66, 67, 68] . In addition, the pharmaceutical industry is 3 increasingly applying precision medicine strategies for the discovery and development of the 4 new treatment modalities and paradigms for AMD. One essential component for implementing precision medicine in clinical practice is the 7 development of in vitro diagnostics (IVD) assays to analyse biomarkers with sufficiently high 8 quality for appropriate clinical decision-making. Therefore, it is essential to understand the 9 constantly evolving regulatory principles governing the development and use of IVDs both in 10 the USA and in the EU (including prospective changes in EU legislation 20 IVDs, but the new EU Directive 2017/746 (released on April 2017) will considerably change 21 the regulation once it comes into force in 2022. The ongoing research strategies in AMD will 22 need to be ready for the new regulation [72] . 23 What is common between Europe and the USA is that approval and commercialisation of 24 IVDs are based on risk classification. For the FDA regulation, risk is determined by the 25 intended use of the IVD test. Class I devices (lowest risk) are subject to the least stringent 26 control regulations including device registration, adverse event reporting and Good
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Manufacturing Practice (GMP) practice requirement; while Class II IVDs are required to 28 include post-market surveillance activities as well the submission to FDA many premarket 29 data demonstrating safety and effectiveness. Such data may include assessment of bias, 30 analytical sensitivity and specificity together with information for the clinical samples 31 analysed by the device. Clinical study data are usually not required for Class II devices but 32 they are obligatory for Class III to assess device performance. The FDA's Center for Devices 1 and Radiological Health (CDRH) is responsible for all IVDs applications. 2 EU has a similar system, assigning commercial IVDs to four classes based on their risk 3 assessment (class I, IIa, IIb and III). Class I is the lowest and class III is the highest risk. 4 Contrary to US where a single federal agency reviews IVDs (the FDA), all Notified Bodies 5 are European Commission accredited independent organizations and are responsible for 6 assigning the CE ("Conformité Européene") mark to all diagnostic products which fulfil the 7 appropriate legal, safety and quality criteria. As most attempts to apply precision medicine 8 principles in AMD also involve IVD diagnostic methods, such as analysis of genetic variants, 9 it is essential to understand the regulatory principals governing their usage. 
Regulation of companion diagnostic in US and EU (present status and perspectives)
. 12 According to the FDA, companion diagnostics "is a medical device, often an in vitro device, 13 which provides information that is essential for the safe and effective use of a corresponding 14 drug or biological product" [73] . The goal of a companion diagnostics (CDx) is to identify 15 patients who will most likely benefit from certain therapeutic product, or identify patients 16 who may exhibit adverse effects because of the treatment, or monitor the response to certain Epidermal growth factor Receptor 2), the result is essential for making the decision on using 20 the therapeutic antibody Trastuzumab (Herceptin®). 21 Several additional regulatory aspects are important for an IVD to be developed as a CDx 22 device. The essential aspects is the coordinated development of both the therapeutic agent 23 and of the CDx device, as they might have co-dependency for approval of both (FDA's draft ]. Only through the introduction of whole genome screening techniques with the ability to 16 interrogate millions of variants in the individual genome a real breakthrough in understanding 17 AMD genetics was achieved.
Genetic tests and genotyping in AMD -prediction, progression and treatment
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A genome-wide association study (GWAS) utilizes specially designed chips to screen for 19 millions of SNPs (single nucleotide polymorphisms) variants in the genome. As it is 20 technically impossible to load every known SNP on a chip, a pre-selection is carried out 21 based on the available haplotype information (SNPs that tend to always occur together). That 22 is, if the presence of certain SNP is confirmed by the chip, adjacent SNP or SNPs can be 23 imputed by the analysis software, and so an almost complete coverage of SNPs can be 24 achieved. It must be emphasised that haplotype structure often varies between different 25 populations based on their different ethnical and/or geographic origin, an important point to 26 consideration so errors in the analysis or interpretation of results are avoided.
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The most common approach in GWAS is the case-control study design when a population of 28 individuals affected by the disease are compared to healthy controls. During the analysis only 29 variants with p-value lower than 10 -8 are considered significant; such stringent condition is 30 necessary to avoid false positive results during the multi-million hypothesis testing procedure 31 [79]. The risk altering properties of variant are expressed as odds ratios (ORs) and 1 corresponding confidence interval (CI). An OR of 1 suggests no change in the risk associated 2 with a certain variant while OR above one signals increased and below 1 signals a decreased 3 risk for a given disease. Common variants associated with complex diseases like AMD 4 usually have low OR (<1.2); alternatively, rare variants (<1%) usually have a high OR>2. 5 Recently GWAS results are often combined with complete sequencing of genes of interest 6 leading to the discovery of not only new common but also new rare variants associated with 7 higher OR values (see below). 8 While family-based genetic linkage studies are appropriate in discovering high-penetrance, 9 low-frequency single gene defects typical for Mendelian diseases. GWAS is particularly well 10 suited for identifying low-penetrance high-frequency genetic variants associated with 11 complex diseases. As such, AMD is well suited for this approach as demonstrated by the 12 discovery of increased AMD risk in individuals with Y420H substitution in the complement 13 related complement factor H (CFH) [80] . In 2013, using 13000 advance stage AMD patients 14 and 60 000 controls from European and Asian descent a study evaluated 2.4 million SNPs 15 and identified 23 loci, 7 of which were novel (COL8A1-FILIP1L, IER3-DDR1, SLC16A8, 16 TGFBR1, RAD51B, ADAMTS9 and B3GALTL). The two known loci in CFH and ARMS2 17 had the highest ORs (, 2.4 and 2.7, respectively), while the novel loci had a modest OR of (IAMDGC) interrogated more than 12 million SNPs and more than 163 000 directly 20 genotyped (sequenced), mainly rare, protein-altering variants and identified 52 variants in 34 21 loci in total, including 7 rare variants with ORs between 1.5 and 47.6. Unfortunately, apart 22 from some protein structure altering variants, it is not always possible to establish direct 23 causal relationship between the loci identified, the adjacent gene (or genes) and the disease 24 itself. Variants localized in non-coding gene expression regulatory sequences (enhancers) 25 may influence the expression level of a gene localized a significant distance away [81] .
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Further non-genomic experimental research in such cases is essential to establish the 27 relationship between suspected gene/locus and the disease of interest.
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Using a variety of bioinformatics tools, the top scoring 34 genes were further analysed. 29 Amongst the 15 newly identified loci with the highest gene priority score (GPS) were the 30 matrix metalloproteinases, COL4A3, an immune function modulator (PILRB), and genes 31 involved in lipid metabolism and inhibitor of the complement system [26]. 32 When nAMD and GA were compared, four variants showed different associations (ARMS2-1 HTRA1, CETP, MMP9 and SYN-TIMP3), but only MMP9 showed exclusive association with 2 nAMD [26]. Comparison of intermediate and advanced AMD showed a significant overlap in 3 genetic determinants (correlation of 0.78 (95% CI=0.69-0.87). Most of those variants were 4 exclusively associated with nAMD and these were related to extracellular matrix remodelling 5 (COL15A1, COL8A1, MMP9, PCOLCE, MMP19, CTRB1-CTRB2 and ITGA7), paving the 6 way for a theory that patients with such variants may progress rapidly to nAMD and may 7 have maximum benefit from future genetic diagnostics and preventive treatment [26]. 10 A fundamental prerequisite of precision medicine is the availability of tests that can correctly 11 predict personalized risk for both development and progression of given diseases. The rapid 12 growth in the number of genetic variants associated with AMD and better understanding of 13 the interactions of genetics and environmental means that such models often incorporate both 14 genetic and non-genetic determinants of the disease for improved accuracy.
Genetic tests as predictive tools for development and progression of AMD
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The most common method to quantify the accuracy of a risk model is to calculate the area 16 under the receiver-operating characteristic (ROC) curve (area under the curve or AUC). The
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ROC curve is generated by plotting the true positive rate (TPR) versus the false positive rate 18 (FPR) at various threshold settings for a given criterion ( Fig. 2) . TPR is also known as 19 sensitivity (proportion of positives that are correctly identified as such) and FPR as fall-out or 20 probability of false alarm and can be calculated by subtracting specificity from one, where 21 specificity is the ratio of true negative and the sum of false positives and true negatives.
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Ideally, AUC must have the value of one (perfect accuracy) so all individuals are correctly 23 assigned to the affected or to the control group. In reality, AUC curves typically acquire 24 values between 0.5 and 1. For screening individuals with increased risk of developing a 25 disease an AUC>0.75 is recommended (tests with AUC>0.9 are considered to be excellent) 26 [82].
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Most tests utilizing only genetic information and trying to predict the risk of development of 86] in studies aiming to predict the progression to advanced AMD and even AUC of 0.94 and 31 0.96 in a study aiming to predict conversion from early-stage to nAMD or GA [87].
1 Surprisingly, a model relying only on clinical/environmental data could predict progression to 2 advanced AMD with high AUC (0.88 in initial sample and 0.91 in validation sample) [88]. 3 The reason for such excellent performance of a non-genetic model is likely to be related to 4 the predictive power of accurate baseline AMD phenotype predicting progression. Other precise phenotyping must underpin any future prediction algorithms. 8 High AUC confers excellent discrimination properties, but it does not guarantee that the 9 model also has good prediction properties of the actual risk of developing disease in the 10 future (good calibration). For prognostic tests both good discrimination (AUC) and 11 calibration indices (measure of how well the predicted probabilities match the actual 12 observed risk) are necessary for accurate risk assessment, the details of which is beyond this 13 current review, but can be studied elsewhere [91].
14 Differences in population genetics may limit the application of current prognostic genetic 15 tests as the majority of AMD genetic associations so far have been studied in populations of 16 European ancestry. This is illustrated by the fact that in Caucasians the common CFH Y402H 29 Currently there is no approved medicine for the treatment of AMD involving the use a 30 companion diagnostics device (CDx). Several studies attempted to identify biomarkers, 31 mainly genetic polymorphisms, associated with the response to anti-VEGF therapy for 1 nAMD (pharmacogenetic studies reviewed by [95] ). The introduction of anti-VEGF therapy 2 had a tremendous positive impact for visual outcomes in patients with nAMD. Taking one of 3 the many trials as an example, in the MARINA trial, on average visual acuity improved by 4 7.2 letters with monthly intravitreal injections of 0.5 mg ranibizumab after 12 months, while 5 in the sham-injection group there was an average loss of 10.4 letters [42] . In the same trial, variants, including in CFH, FZD4, and HTRA1/ARMS2 loci, was associated with response to 20 anti-VEGF [97]. Therefore, there is currently no genetic variants or any other biomarker that 21 could guide the development of a CDx device for decision making in the use of anti-VEGF 22 therapy in nAMD. 23 Development of a CDx device for the recent lampalizumab trial for treating GA was carried 24 out. Lampalizumab, an antigen-binding fragment (Fab) of a humanized monoclonal antibody 25 that targets complement factor D was developed as intravitreal treatment to slow the 26 progression of GA. In the Phase 2 MAHALO trial, a targeted, exploratory pharmacogenetic 27 analysis was performed assessing the possibility that 4 common variants within the 28 alternative complement pathway (CFH, C2/CFB, CFI, and C3) may affect GA progression 29 and lampalizumab treatment response [98] . In the all-comer population, the lampalizumab 30 monthly arm showed a 20% reduction in mean change in GA area progression relative to the 31 pooled sham group at month 18. In the exploratory pharmacogenetics analysis, patients 32 carrying the CFI risk-allele had 44% reduction in GA area progression at month 18 in the 33 monthly lampalizumab-treated subgroup relative to the CFI pooled sham subgroup, although 1 the difference did not reach conventional statistical significance. In the CFI non-risk-allele 2 carrier patients there was no apparent lampalizumab treatment effect compared to sham. The demonstrate that our current understanding of AMD is not detailed enough to allow for such 14 individualised treatment decisions to take place just yet. allow the clustering of patients into ever-more refined and clinically meaningful groups [25] .
Genetic tests as CDx/ Role of genetic tests in Pharmacogenomics
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The interplay between phenotype, genotype [103, 104], environmental [5] or lifestyle [105] 25 are all being considered, but combination of these factors result in a complex interactions. In 26 addition, recent reviews summarized the available potential biomarkers from serum, plasma, 27 aqueous humour, vitreous, and urine of AMD patients [63, 64] . However, none of these has 28 been clinically validated and routinely used just as yet, and as such are awaiting to be 29 included in patient stratification and/or CDx models. Herein, we are focusing on promising 30 biomarkers, suggested in the most recent reviews [63, 64], and summarize many studies 31 which use combinational modelling for patient stratification. 32 In nAMD, clinical features such as age, baseline visual acuity and lesion size showed strong 1 association with anti-VEGF treatment efficiency [106, 107] . However, despite the success of 2 the anti-VEGF therapy, level of VEGF or its related receptors in fluids and tissues do not 3 appear to give reliable indication for therapeutical success. VEGF levels in aqueous humour 4 [108, 109, 110], sera/plasma [111, 112, 113, 114, 115, 116, 117] have been reported to be 5 associated with AMD, however, the results in general are contradictory [63] . It was 6 hypothesized that subgrouping populations for specific genotypes might help identify more 7 significant association of systemic/ocular VEGF fluid level with AMD and help in prediction 8 of therapy response efficiency. However, serum VEGF levels did not correlate with CFH 9 Y402H polymorphism in a case-control study [112] . Other pro-neovascular factors like 10 PEDF and TGF-B1 could be considered as further non-genomic biomarkers, but again, there 11 is a lack of comparison with genotype. TGF-B1 urinary levels showed significant 12 associations with early AMD and can become a candidate non-genomic biomarker. However, 13 there was no correlation with CFH genotype [118] . risk alleles, treatment with antioxidants showed more favourable response upon progression, 20 and neutral or unfavourable responses in 3 genotype groups [120]. 21 The most promising non-genomic biomarker candidates in the oxidative stress pathway 32 carboxyethyl pyrrole (CEP) and its end products [64] and noted that serum CEP level was 1 distinguishable between AMD and control subjects with 72% accuracy, and this increased to 2 92% when CEP and pentosidine were measured simultaneously. 3 Complement activation level (C3d/C3 ratio) has also been associated with AMD, but so far, [134, 135], but neither of that studies were conclusive enough for these to be used for disease 19 or treatment predictions. Serum IgG/IgM ratio levels were elevated in both GA and nAMD 20 [64] and so they do not differentiate enough for these to be used alone clinically. 21 Lipid metabolism components as potential biomarkers for AMD are very well studied and patients. Metabolomics studies are more helpful for pathway identification than identifying 12 biomarker candidates. A recent study analysing plasma samples of neovascular AMD patients 13 and controls identified tyrosine metabolism, amino acids related to urea metabolism and 14 sulphur amino acid metabolism pathways to be significantly affected [150] . 15 MicroRNA profile of AMD patients also, can provide new information for defined diagnosis 16 and or therapy development. Mir23, Dicer and AluRNA has been associated with different pathogenesis. We predict that developing precision medicine for sufferers of AMD will be 15 achieved when clinical and basic scientific information is coupled with advanced 16 bioinformatics and, possibly, appropriate use of artificial intelligence. Combination of 17 phenotype, genotype, environmental factors and yet undefined set(s) of biomarkers will 18 achieve acceptable risk profiling and allow more precise response to treatment prediction.
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In nAMD, new drugs with a different mechanism of action to anti-VEGF antibodies could 20 help those who do not respond to regular injections. This requires identification of relevant 21 pathways for specific geno-and phenotypes so selection of intervention could be better 22 tailored. Personalised therapies will have to cater for the large patient population with GA. As 23 progression and visual loss is slow in GA and not imminent in early AMD, personalised 24 medicine will have to rely on new biomarkers to achieve high diagnostic accuracy and low 25 complication rates, allowing good response in those who have a chance to respond, but not 26 treating anyone for whom such treatment might be detrimental.
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Our understanding of precise clinical phenotypes for AMD appears to be far from complete.
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New imaging modalities and careful analysis of these can lead to visualisation of new 29 phenotypes, potentially leading to identification of important clinical features, is was the case 30 for reticular pseudo-drusen. This phenotype is seriously under-represented in earlier studies but recently with a consensus in their definition, classification and approaches to their valid 1 and reproducible quantification is helping to determine their role as independent factor in 2 prognostic modelling [167] . It appears, that re-classification of AMD features and stages 3 might be appropriate to take the first steps towards precision medicine approaches. The 4 establishment of large data-and image-sets organized in searchable databases, together with 5 appropriate reporting of prospective studies leading to reliable meta-analyses [168] will 6 significantly accelerate the identification of relevant clinical, genetic and environmental 7 factors. In turn, these will lead to personalised medicine being appropriately applied in 8 clinical practice for AMD. This will reduce the financial and societal burden of AMD-related 9 blindness, help to refine treatment approaches tailored to the individual. With this, the future 10 appears to be brighter to those with different forms of AMD.
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Expert opinion 12 Precision medicine has a real potential to revolutionise the care provided to AMD patients.
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The promise that new precision medicine approaches will allow the reduction of AMD 14 related visual loss, despite the exponential growth in the number of aged individuals around 15 the World, is very appealing. The benefit delivered by personalised approached is shared 16 between affected individuals, their care providers as well as the wider society. Retaining 17 independence longer by reducing or delaying the onset of visual loss and the consequent 18 comorbidities will deliver very significant financial benefit for the health service sector too. It 19 is clear that the need to deliver existing therapies to individuals who would definitely benefit 20 from these is paramount. Then, designing new therapeutic approaches to those who could not 21 yet be treated is both an exciting and a daunting task at present. The co-development of new 22 therapeutic agents with companion diagnostic devices with demonstrable clinical utility will 23 undoubtedly require new approaches, new knowledge and new ways to analyse the 24 information generated. 25 In nAMD, new drugs with a different mechanism of action to anti-VEGF antibodies will help 26 those who do not respond to the current regular injections. There are several new molecular 27 pathways and molecular targets interrogated at present, raising the hope that this most 28 aggressive form of and stage AMD will benefit from new approaches. The progression of GA 29 and early AMD is slow compared to nAMD, therefore, personalised medicine approach will 30 have to rely on new imaging and molecular biomarkers to achieve high diagnostic accuracy 31 and a low complication rates, allowing good response in those who have a chance to respond, 1 but not treating anyone for whom such treatment might be detrimental. 2 Our better understanding of the varied clinical phenotype of the different forms of AMD is 3 advancing, but it is far from complete. New imaging modalities are introduced to visualize 4 previously not appreciated phenotypes, some of which can subsequently led to identification quantification. In addition, a concerted effort will be required to define the molecular 9 composition and the cellular processes behind the development of this, and any other new 10 phenotype(s) before we could use these as independent prognostic indicators and a druggable 11 target. The ongoing close multidisciplinary collaboration between clinical and basic scientists 12 is proving to be successful in tackling the complex problems of multifactorial diseases like 13 AMD, raising the hope that sooner rather than later we will be in the position to deliver 14 precision medicine for more and more AMD sufferers.
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The improvement and diversification of new clinical and basic research information come 16 with challenges. While the establishment of large data-and image-sets are being organized 17 into searchable databases processing of these information will require the use of deep 18 learning and artificial intelligence approaches. These, together with the planning of 19 registered, prospective studies and a cooperative environment with sharing of individual 20 patient data to ease meta-analyses will significantly accelerate the identification of most 21 relevant clinical, genetic and environmental factors and in turn, will lead to better precision 22 and as such, personalised medicine practices for AMD. 23 While progress is somewhat currently held back by our rudimental understanding of 24 molecular mechanisms underpinning the initiation and progression of AMD, there is every 25 chance that this will change rapidly. Naturally, we hope to completely alleviate AMD, 26 however, it is important to consider that we might not need to be able to stop the disease 27 completely. It might be just as beneficial to slow the progression of the disease to the point 28 that it is unlikely that it would lead to significant visual loss, a potentially more achievable 29 target.
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Five-year view 32 With the decreasing cost of whole genome sequencing in the next five years there will be a 1 significantly better understanding of the genetic background of AMD. Illumina recently 2 announced that whole genome technology will be available at $100 per patient. In addition, 3 with broader approaches identification and integration of new biomarkers and molecular 4 pathways into disease stratification will be driving patient selection for clinical trials. The 5 better stratification will allow significantly improved precision in study design. With the 6 ever-increasing precision and availability of clinical imaging modalities and emergence of 7 big data sets for every participant, machine learning and artificial intelligence will help faster 8 and more precise phenotyping. The introduction of artificial intelligence will also enable 9 development of significantly improved prediction models leading to discoveries of prognostic 
